Sinovac Biotech Ltd. – NasdaqGS: SVA
Another 52 week stock. This one hit it on Friday at $5.20.
They reported outstanding results in their press release of August 13th: (unaudited numbers)
Second Quarter 2013 Financial Highlights (period-over-period comparisons to second quarter 2012)
- Total sales increased by 86.4% to $17.5 million from $9.4 million.
- Gross profit increased by 70.1% to $13.6 million from $8.0 million.
- Net income attributable to common stockholders was $1.3 million, or $0.02 per basic and diluted share, compared to net loss attributed to common stockholders of $1.6 million, or $0.03 per basic and diluted share.
- Cash and cash equivalents totaled $92.0 million as of June 30, 2013, compared to $91.2 million as of December 31, 2012.
This one is strong.
SEE SVA IN STOCKGURU’S 12 BIOTECH BREAKOUT STOCKS
SEE THE ENTIRE LIST OF STOCKGURU’S 12 BIOTECH BREAKOUT STOCKS